



## ***Impromptu Seminar***

- New Technology of Drug Discovery and Development -

**JKiC 1F** seminar room  
at the north end of the campus

This seminar is introduction of new technology developed by a venture company.

---

**Tue, May 8th, 2018**

**18:00 -19:00**

**Jonathan Solomon**

CEO and a member of Board of Director  
BiomX Ltd.

***"BiomX, Targeting Chronic Microbiome Diseases by Phage"***

---

**Host: A. Shiota, Adjunct Professor, Department of Microbiology & Immunology  
and Microbiome Area Leader of JKiC**

---

BiomX is a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets.

The Company's platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset, and SBI.

\*Conflict of Interest (COI) of the Presenter: No Potential COI to disclose.